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ABSTRACT 
 
Myotonic dystrophy type 1 is caused by a toxic CUG RNA repeat expansion in the 3’-
UTR of the DMPK gene that sequesters a key splicing regulator, MBNL1, preventing normal 
modulation of alternative splicing of a variety of genes. Targeting these repeats with small 
molecules could block the sequestration of MBNL1 and restore normal splicing levels, 
alleviating the pathogenesis of the disease. To that end, I have screened a library of select 
compounds, chosen for their potential to act as RNA binding ligands. From the initial screen, I 
identified several promising lead compounds. I proceeded to perform a structure-activity 
relationship (SAR) study on one of the lead molecules, NSC657704. Based on the results of the 
SAR, I designed a set of derivatives, synthesized them, and ascertained their inhibitory activity 
and RNA binding affinity. 
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CHAPTER 1 
MYOTONIC DYSTROPHY AND SEARCH FOR THERAPEUTICS 
 
1.1 Myotonic dystrophy pathogenesis 
Myotonic dystrophy is an inherited autosomal dominant genetic disorder that affects 1 in 
8500 individuals worldwide.
1
 There are two forms of the disease that share similar symptoms 
and pathogenesis. Type 1 (DM1), the most common type of muscular dystrophy, is typified by a 
(CTG)n trinucleotide expansion within the dystrophia myotonica protein kinase (DMPK) 3’-
untranslated region on chromosome 19.
2,3
 Type 2 (DM2) is related to a (CCTG)n tetranucleotide 
expansion in intron 1 of the zinc finger 9 gene.
1
 Both types of muscular dystrophy exhibit similar 
symptoms, such as myotonia, muscle wasting and cardiac effects.
4
 
Increasing evidence supports the hypothesis that an RNA gain-of-function mechanism is 
the main cause of DM1 pathogenesis. While normal individuals have 5 to 37 repeats, those with 
DM1 have anywhere from 50 to over 3,000 repeats.
5
 RNA-binding proteins, namely splicing 
regulators, become bound to the RNA expansion, resulting in sequestration of the proteins and 
formation of nuclear foci. The splicing regulators are unable to perform their normal functions 
and disruption of alternative splicing occurs. The splicing regulator thought mainly to be 
sequestered is muscleblind-1 (MBNL1), which is involved in alternative splicing for a variety of 
genes which are shown to be affected in DM1 cells.
6
 Not all of the pathogenic events involved in 
myotonic dystrophy can be explained by direct involvement of MBNL1 in splicing regulation, 
which has led some researchers to investigate the involvement of trans elements in the 
sequestration as well. 
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1.2 Toxicity of RNA repeats 
 Whereas evidence was obtained that nucleotide repeat expansions on the DMPK gene 
result in sequestration of the gene in the nucleus and a reduction of DMPK protein in skeletal 
muscle
7
, the loss of protein expression was only modest and did not result in a phenotype that 
matches that of  DM1.
8
  Swanson and coworkers were the first to postulate that the extended 
nucleotide expansions could be sequestering other proteins and preventing them from performing 
normal functions, also known as the RNA gain-of-function hypothesis.
9
 Thornton and coworkers 
were among the first to give supporting evidence to this hypothesis. Using UV thermal melting 
studies and mobility shift assays, they showed the RNA repeats could form stable hairpin 
structures and could bind protein kinase R (PKR), which is activated by binding double-stranded 
RNA.
5
 They also used in vitro kinase assays to show that the pathological CUG repeats could 
activate PKR activity. Krzyzosiak and coworkers performed biochemical structural analysis of 
RNA trinucleotide repeat transcripts and found that all CNG motifs (N=C, G, A, U) form very 
stable hairpins.
10
 These results gave the first direct evidence the pathogenesis of DM1 could be 
due to a gain of function mechanism by the RNA.
5
  
Further evidence to support this hypothesis came from Monckton and coworkers who 
showed that repeat length is directly correlated to age at onset of symptoms and that there is no 
threshold for this correlation, suggesting that the pathogenesis is not related to just a molecular 
‘on’ switch, such as retention of the DMPK gene in the nucleus.11 Also, they found that the more 
rapidly the repeat expansion occurred in a patient, the earlier the onset of symptoms. Phillips and 
coworkers generated a mouse model in which the DMPK 3’-UTR was included in a transcript 
expressing green fluorescent protein (GFP). Overexpression of the transcript led to reproduction 
of DM1 pathogenesis in the mice, including RNA splicing abnormalities, cardiac defects, and 
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myotonia. These symptoms were reversible under transgene silencing, offering further evidence 
of the toxicity of the RNA repeats. The stable repeat structures could be potential therapeutic 
targets that modify RNA toxicity.
12
 
 
1.3 Sequestration of MBNL1 
Once the toxicity of CUG repeat expansions in DM1 had been demonstrated, the 
mechanisms by which these RNAs became toxic became the topic of interest for researchers. It 
was known that the toxicity of expansion repeats in DM1 was associated with global missplicing, 
implicating that the splicing machinery was somehow involved.
13
 Swanson and coworkers were 
among the first to present evidence of splicing regulators being sequestered with the RNA 
repeats. In this seminal study, Swanson performed crosslinking studies with radiolabelled CUG 
repeats of varying lengths in HeLa nuclear extracts.
14
 What they discovered was that the longer 
repeats were bound to a 42kDa protein, referred to as hEXP42. Trypsin digest and mass 
spectrometry analysis revealed the identity of this protein was MBNL1. They also performed 
fluorescent in situ hybridization (FISH) and immunofluorescence microscopy with an MBNL1 
antibody to show that MBNL1 was colocalized with the nuclear foci in cells. Swanson later 
published electron microscopy data showing MBNL1 bound to CUG repeats in a ring-like 
‘donut’ shape.15 
Reddy and coworkers further expanded upon the immunofluorescence analysis by using 
antibodies to purify complexes containing MBNL1 from normal and DM1 myoblasts.
16
 In 
normal myoblasts, 10 proteins were isolated along with MBNL1, including various 
heterogeneous nuclear ribonucleoproteins (hnRNP) and three DEAD box RNA helicases (DDx5, 
DDX17, DDX19). In DM1 myoblasts, only MBNL1 was found to be colocalized with the 
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extended repeats, but steady-state levels of the nine other proteins were found to be increased 
compared to levels found in normal myoblasts. Chartrand and coworkers used MS2-GFP to track 
single RNA transcripts and fluorescence recovery after photobleaching (FRAP) experiments to 
show that the MBNL1 colocalized with individual CUG repeats.
17
 They also showed that RNAi 
silencing of MBNL1 led to decreased aggregation of CUG repeat transcripts after FRAP, which 
indicates MBNL1 has a direct role in the formation of nuclear foci. 
 Berlgund and coworkers conducted in-depth biochemical analysis to determine how 
MBNL1 binds to CUG repeat RNA. They found that only six base pairs were necessary for 
binding, with a preference for sequences containing pyrimidine mismatches.
18
 They also 
examined MBNL1 binding to cardiac troponin T (cTNT) pre-mRNA, and showed that it targets a 
helical region of a stem-loop containing two pyrimidine mismatches, indicating that the natural 
targets of MBNL1 may all contain a 5’-YGCY-3’ motif, where Y is a pyrimidine. Following 
this, Patel and coworkers published a crystal structure of zinc fingers 3 and 4 of MBNL1 bound 
to a CGCUGU RNA sequence, showing how MBNL1 recognizes the 5’-UGCU-3’ motif.19  
Our group has also investigated the binding mode of MBNL1 with CUG repeat RNA 
using steady-state fluorescence quenching experiments.
20
 Upon binding, MBNL1 caused a 
decrease in quenching, which would suggest an alteration in the helical structure to a more 
single-stranded state. Also, removal of one pair of zinc fingers greatly decreased the binding 
affinity of MBNL1, which would most likely indicate that the four zinc fingers interact with the 
RNA in a cooperative manner. 
 
 
 
5 
 
1.4 Disruption of alternative splicing: not the whole picture  
 As previously mentioned, MBNL1 is a splicing regulator, involved in alternative splicing 
of a variety of genes. After investigating the mechanism through which MBNL1 becomes 
colocalized with nuclear foci, Berglund and coworkers searched for the YGCY motif in the 
sequences of 24 pre-mRNA transcripts that are found to be misregulated in DM1.
21
 What they 
found was that for exons that were normally excluded, the upstream intron would be enriched in 
YGCY motifs, while exons that are normally included would be located upstream of such an 
intron. Around the same time, Ares and coworkers performed a splicing microarray to compare 
mRNA levels in two mouse models, one expressing a CUG repeat expansion and the other an 
MBNL1 deficient model.
22
 They identified over 200 splicing events related to MBNL1, and 
showed a strong correlation in misregulation of splicing in DM1 for approximately 100 MBNL1-
regulated exons. Whereas Ares could show over 80% of splicing misregulation in DM1 could be 
attributed to MBNL1 deficiency, the same could not be shown for changes in mRNA levels. This 
led Ares to postulate that the CUG expansion repeats have two pathological pathways: disruption 
of splicing via loss of MBNL1 and loss of some other function that causes disruption of mRNA 
regulation. Evidence of the involvement of some other mechanism has also been demonstrated 
by Reddy and coworkers. As mentioned previously, Reddy showed the colocalization of nine 
other proteins with MBNL1 in normal cells but not in DM1 cells. However, in DM1 myoblasts, 
the steady-state levels of those other proteins were elevated in comparison to normal 
myoblasts.
16
 By changing the levels of the individual proteins in normal myoblasts dysregulation 
of splicing could be observed, indicating the MBNL1 was not the only splicing factor involved. 
In their study, Phillips and coworkers found that transgenic mice expressing a CUG expansion 
repeat not only displayed the pathogenesis of DM1, but also had elevated levels of CUG binding 
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protein (CUG-BP1) in their skeletal muscles.
23
 Another factor could involve the fact that 
MBNL1 regulates its own splicing. Berglund and coworkers have shown that one of the 
missplicing events in DM1 is the inclusion of exon 5 in MBNL1 pre-mRNA. Using a minigene, 
they showed that MBLN1 regulates the inclusion of exon 5, and that deletion of an unstructured 
element in intron 4 led to complete inclusion of exon 5.
24
 This evidence would indicate that 
sequestration of MBNL1 by CUG repeats would have a greater effect on splicing misregulation, 
since MBNL1 expression levels would be negatively affected as well. A recent paper by Marie 
and coworkers brings into question whether MBLN1 is the only protein that becomes 
sequestered. Whereas Reddy had shown that the DEAD box helicases were not involved in the 
nuclear foci in DM1 cells, Marie found that helicase p68 (DDX5) colocalized with MBNL1.
25
 In 
addition, Marie found that the helicase increased binding affinity of MBNL1 for the CUG 
repeats and one of its natural targets, cTNT pre-mRNA. Mutation of helicase p68 resulted in a 
decrease in MBNL1 binding with CUG repeat RNA. Marie suggested that the helicase could be 
modulating the structure of the CUG hairpin in order to facilitate MBNL1 binding. Further 
exploration of these trans elements and how they affect MBNL1 are needed to gain a more 
detailed picture of DM1 pathogenesis. 
 
1.5 Targeting RNA as a therapeutic approach to DM1 
 Based upon the biochemical analysis discussed previously, targeting RNA appeared to be 
a feasible therapeutic approach to DM1. One strategy would be to simply remove part or all of 
the toxic RNA expansion so nuclear foci can no longer form. Lai and coworkers designed an 
antisense oligonucleotide (AON) attached to an artificial trans-splicing molecule targeting exon 
14 of the DMPK pre-mRNA. Using a DMPK minigene, they showed that the trans-splicing 
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molecule was able to splice the endogenous DMPK gene sequence into the minigene, so the 
toxic RNA repeats were not transcribed, but only at efficiency ranging from 2 to 7%.
26
 Furling 
and coworkers took a slightly different approach, attaching a (CAG)n AON to an engineered 
human U7 small nuclear RNA (hU7-snRNA) which resulted in the selective degradation of 
DMPK transcripts containing expanded repeats.
27
 Cooper and coworkers used a very similar 
approach except that they included a sequence to recruit RNAse-H, resulting in degradation of 
the toxic transcripts.
28
 
Another strategy would be to simply block the CUG repeats to prevent MBNL1 
sequestration. Thornton and coworkers designed a morpholino-based AON targeting the 3’ splice 
site of exon 7a of the chloride channel (ClC-1).
29
 Administration of the AON resulted in 
upregulation of mRNA levels and ClC-1 protein expression by repressing inclusion of exon 7a. 
Later they used a similar strategy, except that they targeted the RNA repeat expansion first with 
a (CAG)7 AON then with a morpholino-based (CAG)25 AON.
30,31
 Administration of the CAG 
AONs resulted in dispersement of the nuclear foci observed by microscopy and a return to 
normal alternative splicing in ClC-1.
31
  
The first report of using small molecules as a potential therapeutic against DM1 was 
published by Kira and coworkers in 2005.
32
 They created a DM1 cell model by transfecting a 
plasmid expressing luciferase with a (CTG)250 subcloned into the 3’-UTR region of the minigene 
into a PC12 rat neuronal cell line. Lactate dehydrogenase activity (LDH) was determined as a 
measure of cytotoxicity.  Since the model cell line containing the (CTG)250 repeat underwent 
oxidative stress leading to cell death, the researchers screened a panel of 235 bioflavonoids, 
which are known to be antioxidants, to determine if cytotoxicity could be ameliorated. The most 
active compounds are shown Figure 1.  
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Figure 1. Flavonoids with activity against DM1 cell model containing (CTG)250 repeats 
 
Whether the flavonoids were binding the repeat expansion was not explored by Kira, but a later 
study by Tajmir-Riahi and coworkers examined binding of flavonoids, including several of the 
ones in Figure 1, to calf thymus DNA and yeast tRNA by FT-IR and UV-Vis spectroscopy.
33
 
The flavonoids appeared to be mixed mode binders in general, showing interactions with the 
phosphate backbone and nucleobases by FT-IR spectroscopy, which would indicate groove 
binding. UV analysis showed a red shift of the flavonoid-nucleotide complexes along with a 
decrease in signal intensity, which would indicate intercalation. All of the flavonoids bound with 
moderately good affinity, which some compounds having a Kd lower than 50µM.  
 Berlgund and coworkers utilized mobility-shift assay and radiometric analysis to screen a 
small set of compounds for inhibitory activity of the MBNL1-CUG RNA complex.
34
 They 
identified two small molecules, pentamidine and neomycin. However, pentamidine was the only 
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one that restored correct alternative splicing in the in vitro splicing assays for the cTNT and IR 
genes. The molecule is not very selective for the target RNA, however. Also, the compound 
seemed to have an effect on the exon splicing of cTNT even when the CUG repeat expansion 
was not present in the control cells. The authors explained that this could be due to the molecule 
binding the natural target of MBNL1 in the pre-mRNA, essentially functioning as a synthetic 
replacement of MBNL1 function. 
 
 
Figure 2. pentamidine 
 
Mergny and coworkers selected a small library of 33 chemicals, which had been 
previously identified as DNA or RNA binders, and screened them for binding affinity via 
fluorescence resonance energy transfer (FRET) melting assay.
35
 They found that intercalators, 
such as acridine base molecules, showed the highest affinities, and with an alkylamino-linked 
acridine trimer showing the highest affinity. The major drawback to this compound is the 
complete lack of selectivity over targets, as its mode of binding is mainly through intercalation 
and electrostatic interactions. 
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Figure 3. Trisacridine identified from FRET assay 
 
Zimmerman and coworkers solved the problem of selectivity with the acridine-based 
molecules by attaching a melamine motif via a short alkylamino chain to the acridine.
36
 
Isothermal calorimetry (ITC) analysis showed that the ligand bound with higher affinity for U-U 
mismatches over C-C (6-fold), A-A (>143-fold), or G-G (>143-fold) mismatches. The 
compound showed excellent inhibitory activity via gel mobility-shift assay, even in the presence 
of tRNA as an RNA binding competitor. 
 
 
Figure 4. Melamine-acridine conjugate ligand 
 
Miller and coworkers performed a larger screen based on a resin-based dynamic 
combinatorial library, which covered a theoretical range of 11,325 compounds, to identify lead 
molecules capable of inhibiting the MBNL1-CUG RNA interaction. In this manner, they hoped 
to identify hits with greater selectivity as well as activity.
37
 Several compounds were found to 
have excellent inhibitory activity. 
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Figure 5. Compounds identified from dynamic combinatorial library 
   
Further research revealed that these compounds were not only active in vitro but in vivo as well, 
showing displacement of nuclear foci and correction of alternative spicing in a mouse model.
38
  
 Disney and coworkers have taken a slightly different approach, by selecting molecules 
that have only weak to moderate affinity and activity and building them in a modular manner to 
create multimeric structures with very high affinity and activity. The first set of multimers they 
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designed was based on a derivative of Hoecsht33258, a known DNA binder.
39
 Hoechst33258 
was previously found to bind selectively to a thymidylate synthase mRNA. Footprinting studies 
were conducted to show that the molecule was binding to a hairpin motif with a C-C bulge in its 
stem.
40
 By attaching an azide to the Hoechst scaffold and using click chemistry, Disney was able 
to generate multimers on peptide backbones of varying lengths. 
 
 
Figure 6. Multimers of Hoechst33258 
 
 Disney found that the pentamer scaffold showed the greatest activity, with IC50 values in 
the nanomolar range. The pentamer also showed excellent selectivity for RNA over DNA, and 
displayed from 4 to 200 fold selectivity over other RNA motifs. In vivo studies showed that the 
multimer could disrupt nuclear foci and correct splicing dysregulation.
41
 Disney also used the 
same strategy with kanamycin to target CCUG repeats, which are involved in the pathogenesis of 
DM2, and showed that the kanamycin multimers could be made selective for the CCUG repeats 
over CUG repeats.
42,43
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Figure 7. Kanamycin multimers for DM2 
In order to identify novel scaffolds with desired activity and affinity, high-throughput assays 
capable of screening thousands of compounds with an easy yet reliable readout were needed. 
Engels and coworkers generated immortalized myoblast cells from DM1 patients, and then 
introduced a minigene containing a ClC-1 luciferase gene in order to monitor intron 2 retention 
of the CLC-1 gene. The assay was validated using ~13,000 compounds, with one compound 
being identified with relatively good activity, triciribine.
44
 
 
 
Figure 8. Lead compound identified from HTS, triciribine 
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 Matsuura and coworkers developed and patented a high-throughput splicing assay by 
transfecting a CTG-containing plasmid into HEK cells and measuring the change in splicing of 
the IR gene.
45
 They validated the assay by screening a library of known pharmaceuticals and 
identified several compounds capable of correcting IR splicing. Several of the compounds also 
showed inhibition of the MBNL1-CUG RNA complex by mobility shift assay. 
 
 
Figure 9. Modulators of IR splicing identified by HT splicing assay 
 
Thornton and coworkers recently published a paper outlining two orthogonal high-
throughput screening assays.
46
 The first one, HTRF, was a FRET assay based on the interaction 
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between terbium and XL665. The terbium was attached to a His-tag antibody and the XL665 was 
attached to streptavidin. Upon binding of His-tagged MBNL1 to a biotin-labeled CUG repeat 
RNA, the terbium would be brought into close proximity of the XL665 and the fluorescence was 
measured at 665nm. The second assay was based upon the previously developed AlphaScreen 
technique, a scintillation proximity assay. A streptavidin-coated donor bead contains a 
photosensitizer (phthalocyanine) to generate singlet oxygen. A nickel-coated acceptor bead is 
contains thioxene derivatives which generate light upon excitation. As in the first assay, when a 
His-tagged MBNL1 and a biotin-labeled RNA are bound together, the two beads are brought into 
close enough proximity to produce photoemission at 520-620nm. The HTRF assay was validated 
using a library of 1280 pharmacologically active compounds (LOPAC
1280
, Sigma-Aldrich) and 
the AlphaScreen assay was used as an orthogonal screen to eliminate any false positive hits from 
intrinsic fluorescence or assay artifacts. Six compounds were identified with IC50 values in the 
low micromolar range. 
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Figure 10. Hit compounds identified from HTRF and AlphaScreen assays 
 
Another technique that has been applied recently to search for active compounds was 
similarity searching. Thornton and Disney used previously identified ligands pentamidine and 
Hoechst33258 as scaffolds for their search of the NCI and eMolecules databases.
47
 
Approximately 40 compounds for each subset were selected for screening, utilizing the HTRF 
assay previously developed by Thornton.   
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Figure 11. Hits identified from chemical similarity search 
 
 Almost half of the selected molecule screened showed activity, with some inhibiting in 
the low micromolar range. The top compounds were checked for RNA selectivity against a 
variety of RNA targets and found that at least one compound, H1, showed a two-fold greater 
selectivity for CUG RNA over other targets.  
 
 
Figure 12. Compound H1 
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Compounds H1 also showed in vivo activity as well, displacing nuclear foci and restoring correct 
splicing of exon 5 of the cTNT pre-mRNA. The low toxicity of H1 was also pointed out as 
indicative of its selectivity, as it did not show any off-target effects. 
 
1.6 Summary 
 The identification of a therapeutic strategy that targets the progenitor of pathogenesis is 
crucial to the development of an effective treatment. Substantial evidence has now been brought 
forth that supports the RNA gain-of-function mechanism in DM1, and that the RNA repeats 
sequester a key splicing regulator, MBNL1. Targeting of the nucleotide repeat expansions by 
antisense oligonucleotides and/or small molecules to displace MBNL1 has been shown to be 
effective in reversing symptoms of DM1 in vitro and in vivo. However, there are still markers of 
pathogenesis that cannot be fully explained by the loss of MBNL1 function. Further research is 
needed to fully understand the disease mechanism so better therapeutics can be designed. In the 
interim, potential therapeutics can be used to help understand what is occurring in vivo and bring 
researchers a step closer to a cure.  
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CHAPTER 2 
SCREENING AND IDENTIFICATION OF HIT MOLECULES 
 
2.1 Introduction 
Interruption of RNA-protein interactions by small molecules has remained a significant 
challenge, mainly because of the difficulty in designing a ligand with both sufficient selectivity 
and affinity to target specific RNA motifs. Due to the presence of the hydroxyl group on the 
ribose backbone, RNA is quite labile and presents a much shallower minor groove than DNA. 
Efforts to improve affinity by adding favorable electrostatic interactions via positively charged 
functional groups on ligands often result in a loss of selectivity, as these interactions often 
interact with the RNA backbone, resulting in non-specific binding. Addition of intercalating 
scaffolds also increase affinity but decrease selectivity, as insertion between base-pairs is also 
leads to non-specific interactions.  
In order to find a small molecule ligand with a desired activity against a certain RNA 
target, it is more effective to screen the molecules in an assay that reports a desired activity rather 
than RNA affinity. To this end, we applied an electrophoretic mobility shift assay to observe 
inhibition of the RNA-protein complex, rather than affinity of the ligand for the RNA. In this 
manner, we hoped to identify ligands with more selectivity for the desired target RNA. Activity 
and affinity of hit molecules could be improved by modification of the molecule scaffold, as will 
be discussed in Chapter 3.  
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2.2 Results and discussion 
2.2.1 Screening design 
 As discussed in Chapter 1, the pathogenesis of myotonic dystrophy involves the 
formation of nuclear foci when the splicing regulator MBNL1 binds to (CUG)n RNA located in 
the 3’-untranslated region of the DMPK gene. The ideal therapeutic would bind selectively to the 
RNA and displace MBNL1, allowing it to resume normal function.  
 
 
Figure 13. Visual representation of experiment design. 
 
To this end, we utilized electrophoretic mobility shift assay (EMSA) to observe whether a 
molecule was capable of interrupting this RNA-protein interaction. The assay we used has been 
described previously
1
, employing a 
32
P-labeled (CUG)n RNA and a truncated form of MBNL1, 
hereafter referred to as MBNL1N. Briefly, RNA and protein are incubated in the presence of a 
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small molecule and the reaction mixture is loaded onto a 6% acrylamide gel at 4°C. Voltage is 
applied so the RNA and its complexes travel distances according to their size, with smaller 
unbound RNA travelling longer distances than the RNA-protein complex. The gels are exposed 
to a phosphor screen which is analyzed by radiometric densitometry to quantitate the bands from 
the reaction mixture. The raw data is converted to a percentage of RNA bound to the protein and 
compared to negative and positive controls to determine level of activity for the molecules.   
 
 
Figure 14. Representative EMSA gel of Kd determination of MBNL1N with (CUG)12 RNA 
 
Some modifications to the assay method were necessary in order to facilitate the 
screening of a large number of compounds with differing activities and facilitate radiometric 
densitometry analysis. At first, we used a (CUG)4 RNA with an ultrastable tetraloop, but there 
were concerns that this motif would not be representative of the interaction of MBNL1 with 
(CUG)n RNA,
2
 so further experiments were performed with a (CUG)12 RNA instead. Glycerol 
was added during preparation of the gels to help prevent streaking of the RNA, as smaller 
biomolecules can diffuse in acrylamide gel when voltage is no longer applied.  
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Figure 15. Representative EMSA gel of small molecule screen under optimized 
conditions. 
 
Instead of incubating the molecule with the preformed RNA-protein complex 
(displacement mode), the molecule was added to RNA only and the reaction mixture was 
incubated for 15 minutes before addition of the MBNL1N (prevention mode). The major concern 
with the displacement mode was that the Koff of the protein could affect the ability of molecules 
with weaker activity to displace the protein with only a short incubation period sufficiently 
enough to produce a discernible change via gel-shift assay. Increasing the incubation period 
could lead to degradation of the biomolecules before analysis by EMSA. In order to avoid 
potential aggregation issues with molecules, a detergent (Triton X-100) was added to the reaction 
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mixture buffer to a final concentration of 0.1%. This change also seemed to affect the affinity of 
MBNL1N for the RNA, as Kd determination for the RNA-protein complex yielded lower values 
than expected. Omission of the detergent from the reaction buffer afforded Kd values similar to 
previously reported.
1,3
  
 
2.2.2 Selection of primary and secondary screening libraries 
 Since EMSA is a medium-throughput method, we chose a selected library of compounds 
for the initial activity screening. The majority of the molecules were selected from the NCI 
compound libraries.
4
 A postdoctoral fellow in our laboratory, Tiziano Tuccinardi, designed a 
pharmacophore model based on a glycerol molecule in the major groove of a (CUG)4 RNA 
crystal structure (PDB ID: 3GLP) and performed a pharmacophore search of the NCI open 
compound set based on three potential hydrogen bond interactions as defined by the hydroxyl 
groups of the glycerol molecule. He then narrowed down the results to 180 molecules that best 
matched the hydrogen bonding pattern.  
 
 
Figure 16. Glycerol bound to (CUG)4 RNA (PDB ID: 3GLP) 
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For the screen we also included compounds from the NCI diversity set that our laboratory 
had on hand. These compounds had been analyzed by previous colleagues as being potential 
RNA binding ligands, so we surmised that any activity from these compounds could be more 
likely due to RNA affinity instead of binding to the protein. In addition, I searched the Protein 
Database for all deposited RNA structures that contained a ligand and selected 3 compounds for 
inclusion in our screen based on their binding modes to RNA in the crystal structures. 
Mitoxantrone (PDB ID: 2KGP) intercalates between two G·C pairs, and is water soluble.
5
 
Acepromazine (PDB ID: 1LVJ) is inserted into a bulge flanked by two uridines in TAR RNA.
6
 
Phenothiazines have been shown to preferentially bind to bulges instead of tetraloops or 
duplexes. Proflavin (PDB ID: 2KD4) was selected because, like mitoxantrone, it intercalates 
between two G·C pairs in a synthetic RNA construct.
7 
 
 
Figure 17. Molecules selected from PDB search: mitoxantrone, proflavin, and acepromazine 
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 Once a hit molecule was identified, we performed dose-dependent analysis via EMSA to 
ascertain whether the activity was due to inhibition of the complex or to aggregation of the 
protein. The percent change in bound RNA was analyzed over a concentration range of the small 
molecule. If a sigmoidal curve was observed from a plot of the data, then the compound is likely 
inhibiting the complex via affinity for one of the biomolecules. If a sudden change in bound 
RNA was observed, or the data did not seem to follow a trend, then we assumed that the 
molecule was most likely causing aggregation or solubility issues. Molecules demonstrating 
dose-dependent inhibition were selected for further analysis.  
 To determine whether the hit molecules had affinity for the target RNA, I performed a 
titration assay via steady-state fluorescence spectroscopy. A TAMRA-labeled (CUG)6 RNA was 
placed in a cuvette in buffer conditions similar to those used in EMSA.  
 
 
Figure 18. TAMRA-(CUG)6 RNA construct used for fluorescence assay 
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The small molecule was titrated into the cuvette in small increments, with an incubation period 
in between each titration to allow the reaction mixture to reach equilibrium. The small molecule 
was also titrated into a buffer solution containing only TAMRA to ensure any change in 
fluorescence observed was not due to interference of the small molecule with the fluorophore. 
The relative change in fluorescence was plotted to determine Kd. 
 Once a hit had been confirmed as having inhibitory activity and RNA affinity, a 
secondary screening library was selected based on the compound structure. A minimal scaffold 
was inputted into the NCI Database search function
4
 to search for compounds with similar 
structures. These compounds were ordered from the NCI and screened as described above.   
 
2.2.3 Expression of MBNL1N 
 The plasmid construct containing the truncated MBNL1N sequence was obtained from 
Maurice Swanson
8
, with a His-6 tag on the C-terminal and a GST tag on the N-terminal end. The 
plasmid was transformed and expressed in E. coli.  Purification involved elution from Ni-NTA 
resin, followed by incubation with GST resin and cleavage of the MBNL1N from the GST tag 
via Precission protease. It was premised that purification via double affinity tags would yield a 
pure protein. However, at higher concentrations in EMSA, we noticed what appeared to be an 
‘aggregation’ band above the MBNL1N-CUG RNA complex. Examination of a more 
concentrated protein stock via SDS-PAGE revealed the presence of a co-purifying contaminant, 
most likely from the lysate.  
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Figure 19. MALDI-MS of impure MBNL1N (top) and SDS-PAGE of purification via anion 
exchange chromatography (bottom) 
 
We employed anion exchange chromatography as described by Berglund and coworkers
2
 to 
remove the contaminant after cleavage from the GST resin. MBNL1N purified in this manner 
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appeared as only one band in SDS-PAGE, even at higher concentrations, and the secondary band 
above the RNA-protein complex no longer appeared in EMSA. One of our undergraduate 
students, Lien Nguyen, analyzed the RNA binding of the impurity via EMSA and found that it 
showed weak affinity (Kd ~238nM), which explained why we observed the second band at 
higher protein concentrations. The purified MBNL1N had a Kd of 25±19nM.  
 
 
 
Figure 20. MALDI-MS of isolated impurity (left) and MBNL1N (right) after anion exchange 
chromatography 
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Compounds were prepared as either 1 or 10mM stocks in DMSO and screened at final 
concentrations of 100µM and 1mM, respectively. As a negative control, one well was loaded 
with a reaction mixture containing 10% DMSO instead of a small molecule. For a positive 
control, we used a molecule previously investigated by our laboratory, supplied by our 
collaborators, Zimmerman and coworkers.
1
  
 
 
Figure 21. Control molecule (Ligand 1) 
 
A total of 250 molecules were screened and analyzed for inhibitory activity. Experiments 
were performed in duplicate. Radiometric densitometry analysis was performed and the data 
converted to a percentage change in RNA bound to the complex in comparison to the negative 
control (DMSO only): 
 
% Activity = [FB RNA (control) – FB RNA (molecule)] / [FB RNA (control)] * 100% 
Where FB = Fraction bound, and control is the sample containing 10% DMSO 
 
Compounds with more than 10% displacement of the RNA-protein complex relative to the 
DMSO control were selected for secondary screening.  
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2.2.4 Hits from primary screening library 
A total of 25 molecules were initially identified as potential hits from the pharmacophore 
screening library, but attempts to obtain similar inhibitory activity in repeat experiments were not 
successful. It was only afterwards that we came to the realization that there could be interference 
with the screen from the loading buffer since it contains a significant amount of glycerol (1.7M), 
upon which the pharmacophore model was based. Analysis of glycerol via steady-state 
fluorescence spectroscopy with TAMRA-labeled (CUG)6 RNA did show a very weak affinity 
(Kd between 500µM and 1mM), which could be why we obtained inconsistent results via EMSA. 
We decided to screen the pharmacophore library via fluorescence anisotropy, which my 
colleague Eric Yen-Jun Ho has undertaken as a separate project.  
 
 
Figure 22. Titration of 50% glycerol into TAMRA-(CUG)6 RNA (two trials) 
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 From the remaining screening library, a total of five compounds were identified with 
weak to moderate inhibitory activity.  
 
 
Figure 23. Compounds selected for further analysis from initial library screening. 
 
All of the hit molecules displayed dose-dependent inhibitory activity via EMSA, but it was 
difficult to obtain IC50 values. Very high molecule concentrations were needed to obtain 
sufficient data point for curve fitting analysis, but most of the molecules exhibited poor solubility 
at the required concentrations, and would often precipitate from the stock solutions. At higher 
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concentrations, precipitation of the highly colored molecules could be observed in the wells of 
the acrylamide gels after electrophoresis. This is what led us to perform the secondary screening 
library, to see whether similar derivatives could be found with better solubility and increased 
inhibitory activity. However, I was able to obtain an IC50 value for NSC657704 of approximately 
290µM (average of two trials), which translates to a Ki of approximately 25µM. 
 
 
 
Figure 24. Representative IC50 data for NSC657704 
 
40 
 
 The hit molecules were evaluated for RNA affinity via steady-state fluorescence 
spectroscopy. The same stock solutions were used that were previously prepared for EMSA. 
Compounds were also checked for intrinsic fluorescence and whether they quenched the 
fluorophore. Proflavin showed weak intrinsic fluorescence when excited at 545nm and appeared 
to quench TAMRA, so the Kd was determined by performing a reverse titration with unlabeled 
(CUG)12 RNA.  
 
 
Figure 25. Representative Kd determination of proflavin by reverse titration assay 
 
 While proflavin showed relatively strong inhibitory activity and high RNA affinity (1µM, 
average of two trials) compared to the other hit molecules, I refrained from including it as a 
scaffold for the secondary screening libraries. This was mainly because proflavin had a variety of 
issues that precluded it from being an ideal scaffold for further derivation, including poor 
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solubility, non-specific binding by intercalation, and intrinsic fluorescence that would cause 
issues in analysis by fluorescence-based assays.  
I was unable to analyze NSC95926 by titration assay as it also appears to interfere with 
TAMRA alone. Upon examination of the cuvette it appeared that the solution had become 
occluded, indicating solubility issues. However, as the theophylline scaffold had been identified 
as a potential RNA ligand,
9
 I decided to search for similar derivatives to see if improved activity 
could be obtained so lower concentrations could be used.  
The hydrochloride salt of mitoxantrone is completely water soluble and has high affinity 
for the target RNA with a Kd of 1.5±0.2µM (4 trials). I had concerns about the specificity of this 
molecule as well, but the alkylamino chains lend themselves to further derivation via simple 
amide couplings so specificity could potentially be improved, and its scaffold was included in 
the secondary library search.  
 
 
Figure 26. Representative Kd determination for mitoxantrone 
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NSC657704 showed modest binding affinity with a Kd of 46±2µM, but the compound 
had shown minimal solubility issues in all of the assays to this point. What made this compound 
more interesting was that a previous colleague, Douglas Warui, had identified NSC657704 as a 
hit against a different RNA target and demonstrated that it could bind RNA, albeit weakly 
(163µM).
10,11
 Since it binds our target with much greater affinity, there could be some selectivity 
for the CUG repeats over other RNA motifs.   
 
 
Figure 27. Representative Kd determination for NSC657704 
 
2.2.5 Hits from secondary screening library 
 A total of 90 derivatives were ordered from the NCI Database for the secondary 
screening library. Compounds were prepared and screened in the same manner as the first 
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screening library. Inhibitory activity is reported a percentage of displacement of the complex in 
comparison to the DMSO control as previously described. Many of the derivatives of NSC95926 
had similar solubility issues as the parent compound, so even though some derivatives showed 
decent activity, this scaffold was not investigated further.  
 
 
Table 2.1. Summary of activity of NSC95926 derivatives (average of two trials). 
 
The derivatives of mitoxantrone had a few derivatives that showed good activity at 100µM, but 
displayed large amounts of aggregation at 1mM. Substitution on the primary alkylamine group 
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seemed to decrease inhibition (645018 and 664909), but still showed relatively good activity. 
Replacement of the secondary amine in the alkyl chain also seemed to have a detrimental effect 
on activity (227207, 317017, 317016, 339683). While this scaffold seems to have a great deal of 
potential, I did not pursue it further at this time. Mitoxantrone is already known as an anticancer 
agent and binds DNA,
5
 so I had concerns over whether derivatives of this scaffold could be made 
selective for the target RNA. Aggregation issues at higher concentrations meant it would be 
difficult to accurately ascertain inhibitory activity of derivatives. 
 
 
Table 2.2. Summary of activity of mitoxantrone derivatives (average of two trials). 
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Of the 65 derivatives of NSC657704, 31% showed weak to modest activity via EMSA. The 
positive hits were examined for RNA affinity via titration assay and it was found that all of them 
had weak to modest affinity, with Kds ranging from approximately 100 to 40µM.  This would 
seem to indicate that the coumarin-heterocycle scaffold could be a general RNA-binding ligand. 
I decided to compile the collected data on the positive hits and examine the structure-activity 
relationship of the derivatives.  
 
 
Figure 28. Summary of NSC657704 derivatives with inhibitory activity at 1mM (average of two 
trials for each compound) 
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2.2.6 Structure-activity relationship analysis 
After compilation of the data from the hit compounds from the NSC657704 derivatives, 
there were a few trends I noticed in the substitution of the phenyl ring and the heterocycle with 
respect to inhibitory activity.  
 
 
Table 2.3. Summary of affinity of activity of SAR compounds (average of two trials for 
each measurement). 
 
It appeared that alkylation of the ortho-hydroxyphenyl group almost completely 
abolished inhibitory activity (NSC657434). If the hydroxyl group is placed on a different 
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position on the phenyl ring there is also a detrimental effect on activity (NSC657574). However, 
if a thioxo group is incorporated into the heterocycle, the effect of the alkoxy group seems to be 
ameliorated (NSC657454). When the hydantoin ring is replaced by a rhodanine, the inhibitory 
activity returns to the same level as the parent compound, even with alkylation of the phenol 
(NSC658489). All of this evidence seems to indicate that if the hydantoin ring of the parent 
compound was replaced with a rhodanine, a more active derivative could be obtained. This will 
be discussed farther in Chapter 3. 
 
2.3 Conclusions 
While the compound library we screened was limited, we can still make some conjectures 
about requirements for an active ligand for inhibition of the MNBL1-CUG RNA complex. All 
five positive hits identified from the initial screen contain some sort of intercalating moiety, 
indicating that intercalation seems to be an important requirement for inhibition of MBNL1 
binding. There are a two reasons why this might be so. An intercalator would greatly improve the 
stability of the stem-loop, preventing any proteins from unwinding the duplex. As mentioned in 
Chapter 1, my colleague Yuan Fu has shown that MBNL1 prefers binding to single-stranded 
RNA, and evidence has recently surfaced that a DEAD box helicase could also be involved in 
MBNL1 binding by unwinding the duplex.
12
 Another reason stems from the binding selectivity 
of MBNL1. Berglund and coworkers showed that MBNL1 prefers a 5’-YGCY-3’ motif.2 
Intercalation between the G·C pairs could prohibit MBNL1 from making crucial contacts in 
order to bind and melt the RNA duplex.  Another observation is that the RNA affinity and 
inhibitory activity do not seem to have a direct correlation with each other. Although the sample 
size is limited, it appears that there is only a slight correlation between inhibitory activity and 
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RNA affinity, but the association is most definitely not linear. This is most likely due to the fact 
that some of the molecules might be making contacts with the RNA that are crucial to MBNL1 
binding, but those contacts do not necessarily improve affinity of the molecule for RNA.  
 While all five positive hits showed promise, I decided that derivatives of NSC657704 
would be the most interesting to continue investigating. The structure of these derivatives would 
seem more likely to be mixed mode binders instead of just intercalators, which could lead to 
more specificity with further derivation. Another interesting point is that over 30% of the second 
generation library screened for this hit showed inhibitory activity and RNA affinity. This would 
seem to indicate that the coumarin-heterocycle scaffold could potentially be a general class of 
RNA-binding ligands, but further investigation against other RNA-protein targets is necessary 
before such a statement could be made definitively.  
 
2.4 Materials and Methods 
2.4.1 CUG RNA radiolabeling and purification 
The RNA construct was purchased from IDT DNA with standard desalting. RNA was labeled 
with 50 μCi[γ-32P] ATP using T4 Kinase (Invitrogen). After incubation for 2 hours at 37°C, the 
reaction mixture was extracted with (25:24:1) phenol/chloroform/isoamyl alcohol and (24:1) 
chloroform/isoamyl alcohol. RNA was separated by precipitation with 70% ethanol. Trace 
ethanol was removed under reduced pressure, and the RNA was diluted into RNA storage buffer 
(sodium citrate) to a concentration of 100µM and stored at -20°C. 
2.4.2 MBNL1N expression and purification 
Plasmid expressing the His6-MBNL1N-GST was obtained from Maurice Swanson (University 
of Florida) and transfected into BL21 E. coli competent cells. Cells were grown in Luria broth to 
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OD600 of approximately 0.5 before IPTG was added to a final concentration of 1-2mM to induce 
protein expression. Cells were harvested after an additional 4 hours and lysed via 
ultrasonification. Cell debris was removed by centrifugation at 12,000g for 15 min. Lysate was 
loaded onto Ni-NTA resin and eluted with 250mM imidazole, then loaded onto GST resin and 
washed before proteolytic cleavage via Precission protease. Eluant was loaded onto Q-sepharose 
resin and eluted with buffer (100mM NaCl, 25mM Tris·HCl (pH 7.4), 5mM BME). Fractions 
containing MBNL1N were pooled and exchanged into storage buffer (100mM NaCl, 50mM Tris 
·HCl (pH 8), 25% glycerol) via Amicon centrifugal filters (3KDa cutoff). 
2.4.3 Determination of inhibitory activity of molecules via EMSA 
Conditions were as previously described,
1
 with the following modifications. Small molecules (1 
or 10mM stock in DMSO, 1µL) were placed in conical tubes. Before dilution, (CUG)12 RNA 
was submitted to slow folding by placing conical tube containing RNA into beaker of almost 
boiling water (~90°C) and allowing to cool slowly to room temperature (~1.5 hours).  An aliquot 
of RNA was diluted with protein binding buffer to 0.44nM and 5.5µL aliquots were added to 
each tube containing small molecules. The RNA-small molecule mixture was allowed to 
incubate for 15 minutes before a 4.5µL of MBNL1N (0.22µM) was added to each and incubated 
for an additional 15 minutes. The final concentrations of the reaction were 0.2nM RNA, 0.1µM 
MBNL1N, and 100µM or 1mM small molecule. 8µL of each reaction mixture was loaded onto 
6% acrylamide gels in 0.5X TB buffer (pH 8.3) at 180V. After 5 minutes, the voltage was 
reduced to 150V and allowed to run for 1-2 hours. Each molecule was run in duplicate for each 
trial. 
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2.4.4 Determination of Kd by steady-state fluorescence assay 
Fluorophore-labeled RNA construct was purchased with HPLC purification from IDT. In a 
fluorimeter cuvette was placed a solution of TAMRA-(CUG)6 RNA (25nM) in buffer (175mM 
NaCl, 20mM Tris·HCl (pH 7.4), 5mM MgCl2, 10%DMSO, 0.05% Triton X-100). The 
fluorophore was excited at 545nm and the emission read at 585nm. Stocks of molecules in 
DMSO (1 or 10mM) were prepared in DMSO. Increments of 1µL were titrated into the cuvette 
and mixed thoroughly. Reaction mixture was incubated for 2 minutes before each spectrum was 
obtained. Titrations were continued until saturation of change in signal was achieved. Raw data 
was converted to relative fluorescence, (F-F0) / (Ff-F0), where F0 is the initial fluorescence and Ff 
is the final fluorescence reading. Relative fluorescence is then plotted versus molecule 
concentration and curve fitting was done via the following equation: 
Y = (m2 * x ) / (m1 + x) 
Where m1 is the dissociation constant and m2 is the asymptotic factor. In order to ensure 
observed change was not due to interference of the molecule with TAMRA directly, a control 
was prepared in a similar manner, replacing TAMRA-(CUG)6 RNA with TAMRA only. 
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CHAPTER 3 
SYNTHESIS AND EVALUATION OF COUMARIN-RHODANINE DERIVATIVES 
 
3.1 Introduction 
Of the hit molecules identified from the initial screening, NSC657704 seemed to be the 
most promising lead for several reasons, most important of which was that it had previously been 
identified as an RNA-binding ligand for a different RNA target.
1,2
 Based on the SAR study in 
Chapter 2, replacing the hydantoin Another factor is that the molecular scaffold appears to be 
composed of both an intercalator (coumarin) and a groove binder (rhodanine). A mixed mode 
binder would be more desirable because it would allow for the development of both greater 
affinity and selectivity.  
Both coumarins and rhodanines have shown a wide variety of pharmacological activity. 
Coumarins are a widely abundant class of natural products from a variety of flora and have been 
screened for a variety of pharmacological activity.
3
 The most well-known pharmaceutical use of 
a coumarin derivative is the anticoagulant warfarin. Coumarins have also been shown to act as 
antimicrobials, antivirals, antioxidants, and anti-inflammatory agents. Rhodanines also display a 
wide variety of pharmacological activity, from antimicrobial, antiviral, anticancer, and anti-
inflammatory. Perhaps the most well-known therapeutic use of rhodanines is the diabetes 
medicine epalrestat.
4
 Taken together, this would seem to indicate that a ligand based on a 
coumarin-rhodanine conjugate scaffold has a good chance of having desirable pharmacological 
activity.  
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3.2 Results and Discussion 
3.2.1 Synthetic design 
Based on the structure-activity relationship study discussed in Chapter 2, I designed a 
coumarin-rhodanine conjugate similar to NSC657704 (657704-2S, Figure 29). To explore the 
structure-activity relationship of the heterocyclic ring further, I also planned the synthesis of 
derivatives containing an N-methylhydantoin ring (657704-M) or a thiazolidinone (657704-S) in 
place of the hydantoin ring.  
 
Figure 29. Design of sulfur-containing heterocycles derivatives 
 
One of the greater challenges for the design of these derivatives was that other than a 
brief description in a patent for NSC657704,
5
 there were no literature protocols available for the 
synthesis of the coumarin-heterocycle conjugates. As a result, a number of issues were 
encountered during synthesis of these derivatives, and the synthetic plan had to be redesigned 
several times before a suitable synthetic method was discovered.  
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As the number of sulfur atoms increased, the solubility of the derivative worsened, which 
prevented analysis of the first set of derivatives by EMSA. However, the solubility of the 
intermediates was sufficient enough to perform a cursory screen of inhibitory activity, and, as 
predicted, replacement of the hydantoin ring with rhodanine increased the inhibitory activity. 
Synthetic intermediates as well as final products were analyzed by steady-state fluorescence 
spectroscopy and compared to the Kd of the parent compound. As the number of sulfurs 
incorporated into the heterocycles increased, so did the affinity of the compound.  
Solubility issues prevented further analysis of the derivatives, so in order to circumvent 
this issue, I designed a derivative incorporating a dimethylamino group on the 7-position of the 
coumarin. Inclusion of a tertiary amino group would improve solubility as well as affinity, since 
positively charged groups can form electrostatic interactions with the negatively charged RNA 
backbone. However, inclusion of the tertiary amine appeared to change the reactivity of the 
coumarin so that conjugation of the intermediates no longer proceeded as previously performed. 
In addition, I discovered that both the coumarin and rhodanine intermediates undergo 
intramolecular degradation when heated, so the overall synthetic scheme had to be redesigned 
again. The desired derivative was finally obtained and investigated via EMSA and steady-state 
fluorescence spectroscopy. Although solubility is still an issue, the inhibitory activity and RNA 
affinity both improved significantly in comparison to the parent compound.     
 
3.2.2 Synthesis of the heterocycle intermediates 
For the hydantoin derivatives, the heterocyclic intermediate was generated by 
Knoevenagel reaction of salicylaldehyde onto the 5-position of the heterocycle in the presence of 
a catalytic amount of piperidine in ethanol.
6
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Figure 30. Synthesis of hydantoin-based intermediates 
The same conditions did not appear to work for the sulfur-containing heterocycles. Reaction 
conditions were changed to sodium acetate and acetic acid.
7
 
 
Figure 31. Synthesis of sulfur-containing heterocyclic intermediates 
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I encountered some difficulty in obtaining pure products for 3 and 4, even after multiple 
recrystallizations. Yields were much lower than expected based on literature precedent for 
similar compounds, especially the rhodanine compound, the reason for which will be discussed 
later in this chapter. 
 
3.2.3 Synthesis of coumarin-heterocycle conjugates 
Initial design involved a one-pot reaction with electrophilic substitution of an acetal onto 
the 3-position of 4-hydroxycoumarin followed by condensation with the heterocycle to form an 
enamide.
8
 
 
Figure 32. Initial synthetic design of coumarin-heterocycle conjugates 
While this reaction has been reported for conjugation of coumarin to primary and secondary 
amines,
9
 when I attempted the same conditions with the heterocyclic intermediates, the major 
product isolated originates from a competing side reaction, which involves homodimerization of 
the coumarin to form dicoumarol.
10
 
 
Figure 33. Synthesis of side product dicoumarol 
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I initially believed that the reason the side product was the major product was because the 
heterocyclic nitrogen was not nucleophilic enough to compete with the nucleophilic carbon of 
the coumarin for the coumarin acetal intermediate that was formed in situ.  I attempted to isolate 
the coumarin methyl acetal intermediate 9,
11
 but found that the acetal was easily hydrolyzed 
during workup to generate the aldehyde 10:  
 
Figure 34. Synthesis of coumarin acetal intermediate and subsequent hydrolysis 
 The purification of 10 proved difficult, as it appeared by TLC analysis that multiple products 
had formed. The ΔRf of the aldehyde versus the side products was not sufficient to achieve 
purification by column chromatography, and a suitable recrystallization solvent could not be 
found, as heating the crude mixture in any solvent resulted in formation of the side product 
dicoumarol. I sought an alternate method to synthesize the aldehyde, and decided upon utilizing 
a Vilsmeier-Haack reaction. According to the first literature protocol I chose to utilize,
12
 the 
reaction of 4-hydroxycoumarin with phosphorus oxychloride in N,N'-dimethylformamide would 
yield the desired product 10. However, I soon discovered that the reaction actually yielded 4-
chloro-3-formyl coumarin 11: 
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Figure 35. Synthesis of aldehyde 11 
My initial search of the literature had been a reaction structure search only for structure 10 as a 
product via SciFinder, so only articles that reported a synthesis with that structure as a product 
were displayed. A reaction structure search with only the starting materials yielded several 
articles
13-15
 reporting the chlorinated derivative 11 as the major product instead of 10.  In future 
literature searches, I always search by both methods to ensure all possible references are 
explored before further synthesis design. 
Once I realized I had obtained 11, I once again had to redesign my synthetic scheme. I 
first considered attempting substitution of the chloro group by a hydroxyl group, but I realized 
that the aldehyde would most likely undergo the Cannizzaro reaction or aldol condensation under 
basic conditions, which would most likely explain why I often observed multiple products via 
TLC analysis in most of reactions involving the formyl-substituted coumarins. Further 
investigation of synthetic methods involving 11 led me to an article where the authors were 
trying to generate tricyclic compounds by reacting secondary amines with 11.
16
 They reported 
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that under certain conditions, an enamine formed that prevented the formation of their desired 
product. They proposed the following explanation: 
 
Figure 36. Proposed mechanism of formation of enamine side product 
The authors found that in the presence of 1.5 equivalents of the amine and 1.5 equivalents of 
base, the enamine could be isolated as the major product for several of the substrates they were 
investigating. However, they did not investigate further, as the enamine was not the desired 
product in their case. 
I attempted to duplicate their conditions with my substrates, but observed no change by 
TLC analysis. I conjectured that the reaction between my substrates might have a higher 
activation energy barrier than those reported by the authors, and that a solvent with a higher 
boiling point might drive the reaction forward. I decided to attempt the reaction in toluene, as I 
thought the azeotropic removal of water might drive formation of the disubstituted intermediate. 
I also replaced triethylamine with Hünig’s base, as it has a higher pKa and might help improve 
the nucleophilicity of the heterocyclic nitrogen. 
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Figure 37. Second synthetic design of coumarin-heterocycle conjugates 
While I managed to obtain the desired products under these conditions, the yields were very low, 
often less than 5%. However, the product would precipitate from the reaction mixture while still 
warm and could be easily removed by gravity filtration to yield pure product. Analysis of the 
products proved difficult due to insolubility in every solvent except DMSO and DMF, in which 
they were only minimally soluble. I decided the best way to address this issue would be to use a 
modified coumarin with additional functional groups to improve solubility, which is discussed 
further in section 3.2.4. 
 
3.2.4 Affinity and activity of intermediates and conjugates 
 To determine whether the whole molecule was necessary for activity or whether one 
portion might be more active than the other, I investigated the inhibitory activity via EMSA for 
NSC657704, 4-hydroxycoumarin and intermediates 1 and 4. At 1mM concentration, NSC657704 
shows almost complete displacement of the MBNL1N-RNA complex. None of the fragments are 
anywhere close to the activity of the parent molecule, but the rhodanine intermediate 4 does 
seem to have slightly more activity than the hydantoin derivative 1.     
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Figure 38. EMSA analysis of NSC657704, 4-hydroxycoumarin, 1, and 4 
Next I examined the two intermediates 1 and 4 by steady-state fluorescence spectroscopy to 
determine their RNA affinity. The hydantoin derivative 1 had a signifcantly weaker Kd  (125µM, 
average of two trials) than NSC657704, while the rhodanine derivative 4 had almost the same Kd 
(45µM, average of two trials). This, combined with the EMSA analysis, gives credence to the 
hypothesis that a coumarin-rhodanine conjugate would be more active than NSC657704.    
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Figure 39. Representative Kd analysis of 1 and 4 
 
As previously mentioned, EMSA analysis of the conjugate molecules 6-8 was not possible due to 
solubility issues. However, much lower concentrations could be utilized for Kd analysis. 
Compound 8 was not soluble in DMSO, so stock solutions had to be prepared in DMF instead. 
Titration of DMF alone into TAMRA-(CUG)6 RNA did not change the fluorescence intensity, so 
it was assumed that DMF was a suitable solvent for assays. The results for compounds 5-8 are 
summarized in Table 3.1 (4 trials per molecule). While compounds 5-7 all have similar affinity, 
the rhodanine conjugate 8 shows a two-fold increase in Kd in comparison to the parent 
compound 5.    
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Table 3.1. Summary of Kd values for compounds 5-8. 
 
3.2.5 Synthesis of dimethylaminocoumarin-rhodanine conjugate 
As mentioned in section 3.2.2, the designed coumarin-heterocycle conjugates were only 
minimally soluble in just DMSO and DMF, prohibiting in-depth analysis of their activity. 
Analysis of RNA affinity by fluorescence spectroscopy supported the hypothesis that 
substitution of a rhodanine into the conjugate molecule could improve affinity of the compound, 
which could lead to greater inhibitory activity. If solubility could be improved, then further 
analysis could be performed. I decided that the best plan of action would be to incorporate a 
tertiary alkylamine onto the phenyl ring of the coumarin scaffold. I conjectured that the coumarin 
portion of the molecule was most likely acting as an intercalator and modifications might affect 
affinity less than substitutions on other portions of the conjugate molecule, as reported in the 
SAR study in Chapter 2.  A tertiary amine could also be beneficial since it would become 
protonated in the buffer solution, increasing water solubility and potentially creating a positive 
electrostatic interaction with the RNA.   
After searching the literature, I found that a coumarin scaffold with a dimethylamino 
group in the 7-position had been reported in several references.
17-19
 It had even been reported that 
the 7-dimethylaminocoumarin motif had shown increased binding to DNA by UV-spectroscopy 
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analysis.
20
 The coumarin scaffold was synthesized in several steps, starting with reaction of 
Meldrum’s acid with dimethylaminophenol21 followed by the Vilsmeier-Haack reaction 
performed as before to generate 4-chloro-7-dimethylamino-3-formylcoumarin.
22 
 
 
Figure 40. Synthesis of dimethylamino-substituted coumarin scaffold 
 
Attempts to couple 13 with the rhodanine intermediate in refluxing toluene produced no 
precipitate. Analysis of the crude mixture by ESI-MS showed that the mass peak of the desired 
product was not present. Attempts to perform the coupling in other solvents under reflux 
conditions also did not yield any product. I attempted to redesign the coumarin intermediate, as I 
assumed that the dimethylamino group was somehow causing the aldehyde to become less 
electrophilic. I attempted several different modifications of the coumarin scaffold, trying to 
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increase the electrophilicity of the carbonyl carbon on the 3-position, none of which seemed to 
yield the desired product. While trying to redesign the coumarin scaffold, however, I came 
across an article which described the intramolecular rearrangement of ortho-
hydroxybenzylidenerhodanine to generate a 3-mercaptocoumarin under basic conditions in 
ethanol.
23
 
 
Figure 41. Intramolecular rearrangement of rhodanine intermediate 
 
Upon examination of mass spectra of previous reaction attempts, I discovered the presence of 
either the mercaptocoumarin or its dimer in most of the reaction mixtures. I had not noticed the 
formation of the side product previously because the Rf by TLC of the rhodanine intermediate 
and the side product are almost exactly the same under the conditions used (20:1 CHCl3/MeOH). 
Now that I had identified the problem, I investigated which conditions could be used without the 
intramolecular rearrangement occurring. However, no matter what solvent was used, whenever 
the rhodanine intermediate was heated, the degradation occurred. I then decided to try a screen of 
reaction conditions at room temperature. I had not considered performing the reaction at lower 
temperatures previously because I had assumed that the reason the reaction was not progressing 
was that the activation energy barrier of the condensation was high. Reactions were monitored 
via TLC for appearance of a new spot. The only reactions that showed any progress contained an 
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equivalent of DIPEA, with the reactions in DMF showing the greatest progression of the 
reaction. ESI-MS analysis of the crude reaction mixtures for C, D, and F showed presence of the 
desired product. 
 
Figure 42. TLC analysis of reaction condition screen; A – dioxane; B – acetic acid; C – DIPEA, 
ethanol (warmed to dissolve); D – ethanol; E – DIPEA, ethanol (no warming); DIPEA, DMF  
 
I repeated the reaction on a larger scale. Product was removed from DMF by precipitation with 
ice-cold water, and contaminants were removed by washing the isolated dark orange solid with 
acetone until wash was no longer colored.  
 
Figure 43. Synthesis of dimethylaminocoumarin-rhodanine conjugate 
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There was concern that the isolated solid might be the formyl intermediate 14, but analysis by IR 
spectroscopy showed the presence of an alpha-substituted ketone C=O stretch at 1700cm
-1
 an 
absence of a aldehyde C-H stretch at 2900 cm
-1
, confirming the correct product 15 was obtained. 
 
Figure 44. IR spectrum of compound 15 
 
 
3.2.6 Evaluation activity and affinity of dimethylaminocoumarin-rhodanine conjugate 
RNA affinity was determined by steady-state fluorescence spectroscopy as previously 
described in Chapter 2. The Kd for compound 15 was found to be 15.0±2.7µM, which is only 
slightly better than compound 8, but the solubility was greatly improved, so EMSA analysis 
could be performed as well. 
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Figure 45. Kd analysis of compound 15 
There were slight signs of aggregation in the wells of the gels at the higher 
concentrations, but radiometric densitometry analysis resulted in sigmoidal curves, indicating 
dose-dependent activity. The IC50 value was determined to be 122±26µM, which translates to a 
Ki of approximately 7µM. 
 
Figure 46. Representative EMSA analysis of compound 15 
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Figure 47. IC50 determination of compound 15 
 
3.3 Conclusions 
 Compounds containing a rhodanine ring in place of hydantoin showed a significant 
increase in inhibitory activity and RNA affinity, as hypothesized. Compound 8 showed a two-
fold increase in affinity over the parent molecule 5, and the dimethylamino-substituted conjugate 
displayed a similar affinity (15.0±2.7µM). While the inhibitory activity of 8 could not be 
determined, the incorporation of the tertiary amine on the coumarin scaffold increased solubility 
of the compound to a sufficient level to allow for EMSA analysis. The IC50 for 15 (122±26µM) 
showed over two-fold increase in activity compared to the parent molecule 5. The addition of the 
positively charged amino group did not seem to improve activity or affinity as significantly as 
expected, but this is most likely due to the amino group not being in a position to make hydrogen 
bond contacts with the RNA. Before further derivation of the scaffold, the most prudent action 
71 
 
would be to obtain a crystal structure of the molecule bound to a CUG repeat RNA. Once the 
binding mode is known, derivation can be planned to incorporate potential hydrogen bond 
interactions to increase affinity and specificity.  
 
3.4 Materials and Methods 
Unless stated otherwise, chemicals were purchased as reagent grade and used without further 
purification. Proton and carbon NMR were obtained in DMSO-d6 on a Varian VXR500 
spectrometer. MS were submitted to the Mass Spectra Facility at the University of Illinois, 
Urbana-Champaign. Analytical thin-layer chromatography (TLC) was carried out on Merck 
silica gel 60G-254 plates (25 mm) and developed with the chloroform/methanol (20:1). Flash 
chromatography was performed with Dynamic Adsorbents silica gel (230-400 mesh) by elution 
with a gradient of chloroform and methanol. Solvents were reagent grade and stored over 4Ǻ 
activated molecular sieves. 
 
Synthesis of 1 and 2: 
Salicylaldehyde (1mmol) was placed in a vial and dry piperidine (2mmol) and either hydantoin 
or N-methylhydantoin (1.1mmol) dissolved in 1mL ethanol was added. The vial was placed in a 
beaker covered by a watchglass and irradiated at 200W for 1 min intervals for a total of 5 min. 
The reaction mixture was allowed to cool before addition of water. Aqueous solution was 
extracted with dichloromethane (3x10mL) and the combined organic extracts were washed with 
5% HCl, brine, dried over MgSO4, filtered and concentrated en vacuo. Compounds were 
recrystallized from ethanol/water. 
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1: 73% yield; 
1
H NMR (500MHz): 11.14 (s, 1H, NH), 10.26 (s, 1H, NH), 7.72 (s, 1H, C=CH), 
7.16 (m, 2H, Ar-H), 6.69 (m, 2H, Ar-H); ESI-MS: 205 (M+1)  
2: 64% yield; 
1
H NMR (500MHz): 10.24 (s, 1H, C=CH), 7.78 (s, 1H, C=CH), 7.19 (m, 2H, Ar-
H), 6.89 (m, 2H, Ar-H), 3.78 (s, 3H, CH3); ESI-MS: 219 (M+1) 
Synthesis of 3 and 4: 
Salicylaldehyde (1mmol) and either 2-thioxo-4-oxazolidinone or rhodanine (1.1mmol) was 
placed in a dry round bottom flask with sodium acetate (3.5mmol) and 10mL acetic acid. 
Mixture was heated to reflux for four hours, cooled to rt, and water was added. Solution was 
stirred at rt another hour then solid was removed by filtration. Products were recrystallized from 
ethanol/water. 
3: 58% yield; 
1
H NMR (500MHz): 10.42 (s, 1H, NH), 7.98(s, 1H, C=CH), 7.33 (m, 2H, Ar-H), 
6.94 (m, 2H, Ar-H); ESI-MS: 222 (M+1) 
4: 43% yield; 
1
H NMR (500MHz): 10.67 (s, 1H, NH), 7.85 (s, 1H, C=CH), 7.32 (m, 2H, Ar-H), 
6.97 (m, 2H, Ar-H); ESI-MS: 238 (M+1) 
Synthesis of 11: 
4-hydroxycoumarin (Sigma-Aldrich) was recrystallized from ethanol/water before use. DMF 
(5mL) was added to a RB flask containing POCl3 (5mL) stirring at 0°C. The solution was stirred 
20 min, then coumarin (2.5mmol) was added and reaction was stirred overnight while coming to 
rt. Reaction mixture was poured over ice and stirred for 1 hr, until solid was formed. Precipitate 
was filtered and air-dried, then recrystallized from ethanol/water. Crystalline yellow solid, 72% 
yield. 
1
H-NMR (500MHz): 10.33 (s, 1H, CHO), 8.10 (m, 1H, Ar-H), 7.72 (m, 1H, Ar-H), 7.37-
7.44 (m, 2H, Ar-H); 13C NMR (500MHz): 186.84, 158.43, 153.3, 135.83, 127.69, 125.66, 
118.24, 117.26; ESI-MS: 209 (M+1) 
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Synthesis of 5-8: 
Coumarin 11 (1mmol) and a heterocycles derivative 5-8 (1mmol) were placed in a dry RB flask 
containing 10mL toleuene. The reaction mixture was heated to reflux for 16 hr. Heat source was 
removed and while solution was still warm, precipitate was removed by filtration and dried en 
vacuo. 
5: 18% yield; 
1
H-NMR (500MHz): 11.14 (s, 1H), 10.26 (s, 1H), 10.05 (s, 1H), 7.54 (m, 1H), 
7.15 (m, 1H), 6.80-6.87 (m, 2H), 6.67 (s, 1H)   
6: 
1
H-NMR (500MHz): 12.32 (bs, 1H, OH), 8.39 (m, 2H ), 7.99 (m, 1H), 7.76 (m, 2H), 7.48-
7.63 (m, 5H), 7.29 (m, 2H), 5.53 (s, 1H), 3.30 (s, 3H)  
7: 
1
H-NMR (500MHz): 12.34 (bs, 1H, OH), 8.38 (m, 2H), 8.03 (m, 1H), 7.76 (m, 2H), 7.49-7.62 
(m, 5H), 7.31 (m, 2H), 5.55 (s, 1H)   
8: 6% yield; 
1
H-NMR (500MHz): 12.33 (bs, 1H), 8.39 (m, 2H), 8.01 (m, 1H), 7.76 (m, 2H), 
7.31-7.51 (m, 5H), 7.31 (m, 2H), 5.52 (s, 1H) 
Synthesis of 12: 
Meldrum’s acid (isopropylidene malonate) was synthesized according to the literature.21 3-
(dimethylamino)phenol (2mmol) and the malonate (3mmol) were placed in a reflux apparatus 
connected to a Dean-Stark trap. Toluene (50mL) was added and the mixture was heated to reflux 
for 16 hr. Solution was cooled to rt and the product was filtered and recrystallized from ethanol. 
Ashen gray solid, 52% yield. 
1
H-NMR (500MHz): 11.95 (s, 1H), 7.56 (m, 1H), 6.70 (m, 1H), 
6.49 (m, 1H), 5.27 (s, 1H) 3.00 (s, 6H) 
Synthesis of 13: 
13 was synthesized from 12 in the same manner as 11 and recrystallized from ethanol/water. 
Dark red crystalline solid, 71% yield. 
1
H-NMR (500MHz): 10.08 (s, 1H), 7.83 (m, 1H), 6.92 (m, 
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1H), 6.62 (m, 1H), 3.14 (s, 6H); 
13
C-NMR (500MHz): 186.98, 159.82, 156.09, 129.06, 108.05, 
97.13, 40.50.   
Synthesis of 15: 
Coumarin 13 (1mmol) and rhodanine 4 (1.5mmol) were placed in a vial with DIPEA (1.5mmol) 
and 5mL DMF. Reaction mixture was stirred for 10 hrs. Water was added and the solution stirred 
an additional 2 hrs. Precipitate was isolated by filtration and washed thoroughly with warm 
acetone until the wash was no longer colored. Orange-yellow powdery solid, 34% yield. 
1
H-
NMR (500MHz): 9.81 (s, 1H), 7.95 (s, 1H), 7.55 (m, 1H), 7.34 (m, 1H), 7.25 (m, 1H), 6.97 (m, 
1H), 6.78 (m, 1H), 6.68 (m, 1H)  
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